Related Experiment Videos
Progressive decrease in nuclear retinoic acid receptor beta messenger RNA level during breast carcinogenesis
1Department of Clinical Cancer Prevention, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Abstract:
Some of the nuclear retinoic acid receptors (RARs) alpha, beta, and gamma and retinoid X receptors (RXRs) alpha, beta, and gamma are thought to mediate the effects of retinoids on cell growth, differentiation, and apoptosis and thereby prevent breast carcinogenesis. We analyzed the expression of mRNAs for the three RARs and RXR-alpha in histological sections of specimens from 70 breast cancer patients, which included adjacent normal tissue, ductal carcinoma in situ, and invasive cancer, using in situ hybridization. RARs alpha, beta, and gamma and RXR-alpha were expressed in 98.1, 98.0, 93.0, and 100% of the adjacent normal tissues. Significant decreases in the number of cases expressing RAR-beta were observed among ductal carcinoma in situ (83.1%) and invasive carcinomas (51.6%), especially among the poorly differentiated cases (77.4 and 35.7 %, respectively). No relationship was found between the expression of estrogen receptor and RAR-beta. These results implicate decreases in RAR-beta expression in breast cancer development and suggest that they are independent of estrogen receptor status.
Insights
Decreased expression of retinoic acid receptor-beta (RAR-beta) is linked to breast cancer development. This reduction occurs in ductal carcinoma in situ and invasive breast cancer, independent of estrogen receptor status.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Retinoic acid receptors (RARs) and retinoid X receptors (RXRs) are crucial for regulating cell growth, differentiation, and apoptosis.
- These nuclear receptors are implicated in preventing breast carcinogenesis.
- Understanding their expression patterns in breast cancer is vital for therapeutic strategies.
Purpose of the Study:
- To investigate the expression levels of RARs (alpha, beta, gamma) and RXR-alpha in normal and cancerous breast tissues.
- To determine the correlation between RAR-beta expression and breast cancer progression and differentiation.
- To assess the relationship between RAR-beta expression and estrogen receptor status in breast cancer.
Main Methods:
- Analysis of mRNA expression for RARs and RXR-alpha using in situ hybridization.
- Study included histological sections from 70 breast cancer patients: adjacent normal tissue, ductal carcinoma in situ, and invasive cancer.
- Quantification of receptor expression in different tissue types and cancer grades.
Main Results:
- High expression of RARs (alpha, beta, gamma) and RXR-alpha was observed in adjacent normal breast tissues.
- A significant decrease in RAR-beta expression was found in ductal carcinoma in situ (83.1%) and invasive carcinomas (51.6%).
- Poorly differentiated invasive carcinomas showed particularly low RAR-beta expression (35.7%).
- No correlation was found between RAR-beta expression and estrogen receptor status.
Conclusions:
- Reduced RAR-beta expression is implicated in the development of breast cancer.
- The downregulation of RAR-beta appears to be an early event in breast carcinogenesis.
- RAR-beta expression changes in breast cancer are independent of estrogen receptor status, suggesting distinct regulatory pathways.